News in brief - pp1070 - 1071

doi:10.1038/nbt1007-1070

Full Text - News in brief | PDF (140 KB) - News in brief

Profile: Alpheus Bingham - p1072

Ken Wilan

doi:10.1038/nbt1007-1072

Abstract - Profile: Alpheus Bingham | Full Text - Profile: Alpheus Bingham | PDF (71 KB) - Profile: Alpheus Bingham

Drug output slows in 2006 - p1073

Stacy Lawrence

doi:10.1038/nbt1007-1073

Full Text - Drug output slows in 2006 | PDF (211 KB) - Drug output slows in 2006

Mice with a human touch - pp1075 - 1077

Christopher Thomas Scott

doi:10.1038/nbt1007-1075

Abstract - Mice with a human touch | Full Text - Mice with a human touch | PDF (137 KB) - Mice with a human touch

Learning how to get along with others - pp1079 - 1081

Dean Stell

doi:10.1038/bioe.2007.3

PDF (103 KB) - Learning how to get along with others

A shocking biodefense editorial - p1083

W Craig Vanderwagen

doi:10.1038/nbt1007-1083a

Full Text - A shocking biodefense editorial | PDF (114 KB) - A shocking biodefense editorial

Response to A shocking biodefense editorial - pp1083 - 1084

doi:10.1038/nbt1007-1083b

Full Text - Response to A shocking biodefense editorial | PDF (133 KB) - Response to A shocking biodefense editorial

The FDA animal efficacy rule and biodefense - pp1084 - 1087

on behalf of the Alliance for Biosecurity

doi:10.1038/nbt1007-1084

Full Text - The FDA animal efficacy rule and biodefense | PDF (191 KB) - The FDA animal efficacy rule and biodefense

Conserving biodiversity using patent law - pp1087 - 1088

Tamás Székely & Alex Gaillard

doi:10.1038/nbt1007-1087

Full Text - Conserving biodiversity using patent law | PDF (140 KB) - Conserving biodiversity using patent law

Why Cabilly must stand - pp1088 - 1089

Richard H Scheller

doi:10.1038/nbt1007-1088

Full Text - Why Cabilly must stand | PDF (100 KB) - Why Cabilly must stand

European regulation tackles tissue engineering - pp1089 - 1091

Ralf Sanzenbacher, Anne Dwenger, Martina Schuessler-Lenz, Klaus Cichutek & Egbert Flory

doi:10.1038/nbt1007-1089

Full Text - European regulation tackles tissue engineering | PDF (292 KB) - European regulation tackles tissue engineering

The power and pitfalls of outsourcing - pp1093 - 1096

Franz B Pichler & Susan J Turner

doi:10.1038/nbt1007-1093

Abstract - The power and pitfalls of outsourcing | Full Text - The power and pitfalls of outsourcing | PDF (344 KB) - The power and pitfalls of outsourcing

Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents - pp1105 - 1106

Rachel Teitelbaum & Mark Cohen

doi:10.1038/nbt1007-1105

Abstract - Obviousness, hindsight and perspective: the impact of : KSR v. Teleflex: on biotech and pharmaceutical patents | Full Text - Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents | PDF (96 KB) - Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents

Recent patent applications in protein purification - p1107

doi:10.1038/nbt1007-1107

Full Text - Recent patent applications in protein purification | PDF (43 KB) - Recent patent applications in protein purification

Many ways to pluripotency - pp1114 - 1116

Robin Lovell-Badge

doi:10.1038/nbt1007-1114

Abstract - Many ways to pluripotency | Full Text - Many ways to pluripotency | PDF (908 KB) - Many ways to pluripotency

Research Highlights - p1117

doi:10.1038/nbt1007-1117

Full Text - Research Highlights | PDF (163 KB) - Research Highlights

Drug—target network - pp1119 - 1126

Muhammed A Yldrm, Kwang-Il Goh, Michael E Cusick, Albert-László Barabási & Marc Vidal

doi:10.1038/nbt1338

Abstract - Drug[mdash]target network | Full Text - Drug—target network | PDF (802 KB) - Drug—target network | Supplementary information

See also: News and Views by Hopkins

The Functional Genomics Experiment model (FuGE): an extensible framework for standards in functional genomics - pp1127 - 1133

Andrew R Jones, Michael Miller, Ruedi Aebersold, Rolf Apweiler, Catherine A Ball, Alvis Brazma, James DeGreef, Nigel Hardy, Henning Hermjakob, Simon J Hubbard, Peter Hussey, Mark Igra, Helen Jenkins, Randall K Julian, Jr, Kent Laursen, Stephen G Oliver, Norman W Paton, Susanna-Assunta Sansone, Ugis Sarkans, Christian J Stoeckert, Jr, Chris F Taylor, Patricia L Whetzel, Joseph A White, Paul Spellman & Angel Pizarro

doi:10.1038/nbt1347

Abstract - The Functional Genomics Experiment model (FuGE): an extensible framework for standards in functional genomics | Full Text - The Functional Genomics Experiment model (FuGE): an extensible framework for standards in functional genomics | PDF (283 KB) - The Functional Genomics Experiment model (FuGE): an extensible framework for standards in functional genomics | Supplementary information

From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice - pp1134 - 1143

Aya Jakobovits, Rafael G Amado, Xiaodong Yang, Lorin Roskos & Gisela Schwab

doi:10.1038/nbt1337

Abstract - From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice | Full Text - From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice | PDF (3,763 KB) - From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice

A simple selection strategy for evolving highly efficient enzymes - pp1145 - 1147

Martin Neuenschwander, Maren Butz, Caroline Heintz, Peter Kast & Donald Hilvert

doi:10.1038/nbt1341

First paragraph - A simple selection strategy for evolving highly efficient enzymes | Full Text - A simple selection strategy for evolving highly efficient enzymes | PDF (143 KB) - A simple selection strategy for evolving highly efficient enzymes | Supplementary information

Mechanisms and optimization of in vivo delivery of lipophilic siRNAs - pp1149 - 1157

Christian Wolfrum, Shuanping Shi, K Narayanannair Jayaprakash, Muthusamy Jayaraman, Gang Wang, Rajendra K Pandey, Kallanthottathil G Rajeev, Tomoko Nakayama, Klaus Charrise, Esther M Ndungo, Tracy Zimmermann, Victor Koteliansky, Muthiah Manoharan & Markus Stoffel

doi:10.1038/nbt1339

Abstract - Mechanisms and optimization of : in vivo: delivery of lipophilic siRNAs | Full Text - Mechanisms and optimization of in vivo delivery of lipophilic siRNAs | PDF (462 KB) - Mechanisms and optimization of in vivo delivery of lipophilic siRNAs | Supplementary information

Exploiting lymphatic transport and complement activation in nanoparticle vaccines - pp1159 - 1164

Sai T Reddy, André J van der Vlies, Eleonora Simeoni, Veronique Angeli, Gwendalyn J Randolph, Conlin P O'Neil, Leslie K Lee, Melody A Swartz & Jeffrey A Hubbell

doi:10.1038/nbt1332

First paragraph - Exploiting lymphatic transport and complement activation in nanoparticle vaccines | Full Text - Exploiting lymphatic transport and complement activation in nanoparticle vaccines | PDF (363 KB) - Exploiting lymphatic transport and complement activation in nanoparticle vaccines | Supplementary information

Renal clearance of quantum dots - pp1165 - 1170

Hak Soo Choi, Wenhao Liu, Preeti Misra, Eiichi Tanaka, John P Zimmer, Binil Itty Ipe, Moungi G Bawendi & John V Frangioni

doi:10.1038/nbt1340

First paragraph - Renal clearance of quantum dots | Full Text - Renal clearance of quantum dots | PDF (461 KB) - Renal clearance of quantum dots | Supplementary information

Computational design of antibody-affinity improvement beyond in vivo maturation - pp1171 - 1176

Shaun M Lippow, K Dane Wittrup & Bruce Tidor

doi:10.1038/nbt1336

First paragraph - Computational design of antibody-affinity improvement beyond : in vivo: maturation | Full Text - Computational design of antibody-affinity improvement beyond in vivo maturation | PDF (349 KB) - Computational design of antibody-affinity improvement beyond in vivo maturation | Supplementary information

See also: News and Views by Shoichet

Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells - pp1177 - 1181

Alexander Meissner, Marius Wernig & Rudolf Jaenisch

doi:10.1038/nbt1335

First paragraph - Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells | Full Text - Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells | PDF (899 KB) - Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells | Supplementary information

The strengths of biotech - pp1183 - 1184

Linda Burak Gretton

doi:10.1038/nbt1007-1183

Abstract - The strengths of biotech | Full Text - The strengths of biotech | PDF (185 KB) - The strengths of biotech

People - p1186

doi:10.1038/nbt1007-1186

Full Text - People | PDF (125 KB) - People